TRENDING :  Market Movers  |  Top 50   UHS (-8.2%)    UGAZ (-22.16%)    TVIX (7.92%)    TSLA (-2.95%)    SRPT (-2.05%)    SPY (-1.85%)    NBEV (0.85%)    MA (-1.83%)    HTGM (-1.97%)    GDX (-1.76%)    FB (-0.66%)    EWC (-1.17%)    CI (-3.11%)    CARA (-0.22%)    BTCUSD (%)    BHC (-3.3%)    ARGT (-1.53%)    AMZN (-4.01%)

 ARWR - Arrowhead Pharmaceuticals

$14.32 (-3.25%)

Next Earnings



Analyst Rating

CompanyAnalyst NamePT ActionActionRatingTargetDate
B. Riley FBRMadhu KumarUpgradesBuy$0.0009/06/18
B. Riley FBRMadhu KumarRaisesMaintainsNeutral$18.0008/08/18
Cantor FitzgeraldElemer PirosUpgradesOverweight$0.0005/09/18
JefferiesMaury RaycroftAnnouncesInitiates Coverage OnBuy$10.0003/27/18
Cantor FitzgeraldElemer PirosRaisesMaintainsNeutral$5.0002/12/18
B. Riley FBRMadhu KumarAnnouncesInitiates Coverage OnNeutral$3.0001/05/18


No recommendations found.

This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.



Why Arrowhead Pharmaceuticals Surged 11% Higher Today

What happened After Arrowhead Pharmaceuticals NASDAQ ARWR reported on its fiscal 2018 financial results on Wednesday and gave new details on the trials it has underway for its RNAi platform shares of the 160 clinical stage biotech rallied by 11 So what The

Arrowhead Pharmaceuticals (ARWR) Q4 2018 Earnings Conference Call Transcript

Image source The Motley Fool Arrowhead Pharmaceuticals NASDAQ ARWR Q4 2018 Earnings Conference Call Dec 11 2018 4 30 p m ET Contents Prepared Remarks Questions and Answers Call Participants Prepared Remarks

After-Hours Earnings Report for December 11, 2018 : AEO, PLAY, ARWR, PHX

The following companies are expected to report earnings after hours on 12 11 2018 Visit our Earnings Calendar for a full list of expected earnings releases American Eagle Outfitters Inc AEO is reporting for the quarter ending October 31 2018 The

Here's Why Arrowhead Pharmaceuticals Jumped 14.1% in November

What happened Shares of Arrowhead Pharmaceuticals NASDAQ ARWR rose over 14 last month according to data provided by S amp P Global Market Intelligence The stock actually had gains nearly double that on Nov 9 when it announced two late breaking poster presentations

J&J Strikes Deal with argenx to Co-Develop Cancer Antibody

Johnson amp Johnson JNJ announced that it has entered into a global collaboration and license agreement with Dutch firm argenx to jointly develop and globally commercializethe the latter s promising antibody cusatuzumab ARGX 110 The candidate is being evaluated in phase I II studies for